'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions

Max Gelman

Senior Editor

Two months after acquiring an AI engine it claims can potentially speed up drug development by “unprecedented” levels,” AbSci has secured a hefty crossover round …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Pro­tein print­ing' Ab­Sci se­cures $125M crossover as it ex­pands syn­thet­ic bi­ol­o­gy am­bi­tions

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions